AzTE Arizona Technology Enterprises

www.azte.com

Methods and Compositions Related to Glycoprotein-Immunoglobulin Fusions

AzTE Case # M10-018

Inventors

Hugh Mason
Professor
The Biodesign Institute
Arizona State University

Seong Hee Bhoo
Research Associate
The Biodesign Institute
Arizona State University

Sun Hee Park
Graduate Assistant
The Biodesign Institute
Arizona State University

Charles Arntzen
Research Scientist
The Biodesign Institute
Arizona State University

Invention Description

More than 170 million people worldwide are chronic carriers of Hepatitis C Virus (HCV), but there is no therapeutic vaccine currently available for treating this infection. Persistent HCV infection results in chronic active hepatitis which may lead to progressive liver disease. Current treatment strategies are expensive, have substantial side effects, and are effective in only approximately 50% of patients. Therapeutic vaccines that enhance host immune responses to eliminate chronic HCV infection would be a major advancement in the treatment of this disease.

Researchers at the Biodesign Institute at Arizona State University have developed a new strategy to produce vaccines against viruses by targeting glycoproteins present on the virus surface. By combining HCV glycoproteins, E1 and E2, with portions of human antibodies (IgG), they produced a novel fusion protein with heterodimeric structure. In addition, they have successfully expressed protein components in plants—a promising medium for high production yields.

The fusion protein system ensures correct presentation of the HCV glycoproteins in their folded states, which guarantees generation of a robust immune response.

Potential Applications

- Strategy to create vaccines against many viruses
- Synthetic vaccine for treatment against Hepatitis C Virus

Benefits and Advantages

- Targets specific functional proteins on viruses
- High yields of protein components with plant based expression
- Specific immunogenicity

Intellectual Property Status:
Patent Pending

Contact

Jack Geltosky, PhD

Senior Vice President
of Business Development, Life Sciences
Arizona Technology Enterprises, LLC (AzTE)
P: 480.884.1989
F: 480.884.1984
JGELTOSKY@AZTE.COM
HEALTHSCIENCES@AZTE.COM